The last several years have seen a palpable enthusiasm regarding ketamine’s potential utility in the treatment of depression, anxiety, and related maladies. This research culminates at present with the work of McInnes and colleagues, sponsored by the healthcare technology company Osmind. This study, from the Journal of Affective Disorders, is the largest outcomes analysis of Ketamine Infusion…


Previous articlePT327 – Rick Doblin, Ph.D. – Confronting Abuse in Clinical Trials and the Future of Psychedelic Medicine
Next articleStephen Bardin to Join atai Life Sciences as CFO Designate